Heart failure affects an estimated 6.5 million adults in the United States, approximately 50% of whom have heart failure with reduced ejection fraction (HFrEF). Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the…
SOUTH BEND, Ind. (WNDU) – This little cowboy was saved by a groundbreaking new therapy.
His live-saving drug was approved just in time.
Details in today’s Medical Moment.
Gene…
Healio Interview
Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences,…
News Release
Wednesday, November 11, 2020
Effective, early interventions would benefit individual patients and healthcare system.
COVID-19 treatments for people…
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult…
source website
WASHINGTON (NewsNation Now) — The U.S. Government has approved an Emergency Use Authorization for an investigational monoclonal antibody therapy “for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients,” the agency said Monday.
The…
AJMC®: Can you discuss how the knowledge base for determining which patients would most benefit from CAR T cell therapy has evolved over the last several years?
Mehta: Primary antigen T-cell receptor therapy has been in practice now for…
This article was originally published here
Curr Opin Pharmacol. 2020 Nov 4;55:73-81. doi: 10.1016/j.coph.2020.09.014. Online ahead of print.
ABSTRACT
Treatment strategies for inflammatory bowel disease (IBD) now increasingly target deep remission, yet the resultant more aggressive use of…
